🚀 VC round data is live in beta, check it out!
Santhera Pharma Valuation Multiples
Discover revenue and EBITDA valuation multiples for Santhera Pharma and similar public comparables like Organogenesis, LENZ Therapeutics, Vicore Pharma Holding, Hansa Biopharma and more.
Santhera Pharma Overview
About Santhera Pharma
Santhera Pharmaceuticals Holding AG is a specialty pharmaceutical company focused on the development and commercialization of products for the treatment of mitochondrial and neuromuscular diseases, an area that includes many orphan and niche indications with high unmet medical needs. It has one operating segment, namely the development and commercialization of products for the treatment of neuro-ophthalmological, pulmonary, and neuromuscular diseases. The company derives the majority of its revenue from the European Union.
Founded
2004
HQ
Employees
85
Website
Sectors
Financials (LTM)
EV
$350M
Santhera Pharma Financials
Santhera Pharma reported last 12-month revenue of $104M.
In the same LTM period, Santhera Pharma generated $51M in gross profit and had net loss of ($31M).
Revenue (LTM)
Santhera Pharma P&L
In the most recent fiscal year, Santhera Pharma reported revenue of $50M and EBITDA of ($33M).
Santhera Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $104M | XXX | $50M | XXX | XXX | XXX |
| Gross Profit | $51M | XXX | $30M | XXX | XXX | XXX |
| Gross Margin | 50% | XXX | 60% | XXX | XXX | XXX |
| EBITDA | — | XXX | ($33M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (67%) | XXX | XXX | XXX |
| EBIT Margin | (22%) | XXX | (80%) | XXX | XXX | XXX |
| Net Profit | ($31M) | XXX | ($51M) | XXX | XXX | XXX |
| Net Margin | (30%) | XXX | (102%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Santhera Pharma Stock Performance
Santhera Pharma has current market cap of $321M, and enterprise value of $350M.
Market Cap Evolution
Santhera Pharma's stock price is $22.55.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $350M | $321M | 0.2% | XXX | XXX | XXX | $-3.58 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialSanthera Pharma Valuation Multiples
Santhera Pharma trades at 3.4x EV/Revenue multiple, and (10.5x) EV/EBITDA.
EV / Revenue (LTM)
Santhera Pharma Financial Valuation Multiples
As of April 20, 2026, Santhera Pharma has market cap of $321M and EV of $350M.
Equity research analysts estimate Santhera Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Santhera Pharma has a P/E ratio of (10.4x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $321M | XXX | $321M | XXX | XXX | XXX |
| EV (current) | $350M | XXX | $350M | XXX | XXX | XXX |
| EV/Revenue | 3.4x | XXX | 7.0x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (10.5x) | XXX | XXX | XXX |
| EV/EBIT | (15.2x) | XXX | (8.7x) | XXX | XXX | XXX |
| EV/Gross Profit | 6.8x | XXX | 11.6x | XXX | XXX | XXX |
| P/E | (10.4x) | XXX | (6.3x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (8.1x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Santhera Pharma Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Santhera Pharma Margins & Growth Rates
Santhera Pharma's revenue in the last 12 month grew by 29%.
Santhera Pharma's revenue per employee in the last FY averaged $0.6M, while opex per employee averaged $0.9M for the same period.
Santhera Pharma Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 29% | XXX | 81% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (67%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (136%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.6M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.9M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 18% | XXX | 28% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 23% | XXX | 50% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 30% | XXX | 68% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 145% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Santhera Pharma Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Santhera Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Organogenesis | XXX | XXX | XXX | XXX | XXX | XXX |
| LENZ Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Vicore Pharma Holding | XXX | XXX | XXX | XXX | XXX | XXX |
| Hansa Biopharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Northwest Biotherapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Santhera Pharma M&A Activity
Santhera Pharma acquired XXX companies to date.
Last acquisition by Santhera Pharma was on XXXXXXXX, XXXXX. Santhera Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Santhera Pharma
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialSanthera Pharma Investment Activity
Santhera Pharma invested in XXX companies to date.
Santhera Pharma made its latest investment on XXXXXXXX, XXXXX. Santhera Pharma invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Santhera Pharma
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Santhera Pharma
| When was Santhera Pharma founded? | Santhera Pharma was founded in 2004. |
| Where is Santhera Pharma headquartered? | Santhera Pharma is headquartered in Switzerland. |
| How many employees does Santhera Pharma have? | As of today, Santhera Pharma has over 85 employees. |
| Is Santhera Pharma publicly listed? | Yes, Santhera Pharma is a public company listed on SIX Swiss Exchange. |
| What is the stock symbol of Santhera Pharma? | Santhera Pharma trades under SANN ticker. |
| When did Santhera Pharma go public? | Santhera Pharma went public in 2006. |
| Who are competitors of Santhera Pharma? | Santhera Pharma main competitors are Organogenesis, LENZ Therapeutics, Vicore Pharma Holding, Hansa Biopharma. |
| What is the current market cap of Santhera Pharma? | Santhera Pharma's current market cap is $321M. |
| What is the current revenue of Santhera Pharma? | Santhera Pharma's last 12 months revenue is $104M. |
| What is the current revenue growth of Santhera Pharma? | Santhera Pharma revenue growth (NTM/LTM) is 29%. |
| What is the current EV/Revenue multiple of Santhera Pharma? | Current revenue multiple of Santhera Pharma is 3.4x. |
| Is Santhera Pharma profitable? | No, Santhera Pharma is not profitable. |
| What is the current net income of Santhera Pharma? | Santhera Pharma's last 12 months net income is ($31M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.